Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma reported consolidated revenue of Rs. 1,303 cr in Q1 FY2026, up 14% from Rs. 1,145 cr a year ago. EBITDA rose 6% to Rs. 351 cr (margin of 27%, down from 29%), while profit after tax grew 4% to Rs. 255 cr (margin of 20%). A Rs. 25 cr mark-to-market forex loss dragged margins; excluding this, EBITDA grew 14% to Rs. 376 cr (29% margin) and PAT grew 12%. US Generics surged 36% to Rs. 310 cr, India Branded rose 16% to Rs. 409 cr, and Asia grew 10%. Africa Branded was flat and Africa Institution fell 8%. Cash flow from operations was Rs. 282 cr with healthy ROCE of 33% and RONW of 26%. Auditors B S R & Co. LLP issued an unmodified limited review opinion.
Steady topline growth and strong US business expansion are positives, but the reported EBITDA margin compression due to forex loss may draw investor attention. Strong cash generation and high return ratios continue to support the stock's quality profile.